3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Terminated
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Plasma cell
1
Other hematologic neoplasm
1
Other
1
Myeloid
1
Conditions
Lymphoma, Non-Hodgkin
2
Hodgkin Disease
2
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Mucositis
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Interventions
Cyclophosphamide
24
Mycophenolic Acid
15
fludarabine phosphate
14
fludarabine
13
Whole-Body Irradiation
13
Tacrolimus
12
Rituximab
12
Melphalan
12
Filgrastim
11
Cyclosporine
11
Busulfan
11
Radiotherapy
10
Peripheral Blood Stem Cell Transplantation
10
Antilymphocyte Serum
10
Methotrexate
9
Doxorubicin
9
Gemcitabine
8
Etoposide
8
Brentuximab Vedotin
8
Sirolimus
7
pembrolizumab
6
Vinblastine
6
Nivolumab
6
Methylprednisolone
6
Granulocyte Colony-Stimulating Factor
6
Alemtuzumab
6
Dacarbazine
5
Cytarabine
5
Cord Blood Stem Cell Transplantation
5
Carmustine
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Terminated
×
Hodgkin Disease
×
angiotensin I (1-7)
×
Clear all
NCT01121120
2020-12-08
TXA127-PBSC
Tarix Pharmaceuticals
Phase 2
Terminated
75 enrolled
NCT01300611
2020-12-08
USBTXA127CBT
Tarix Pharmaceuticals
Phase 1
Terminated
20 enrolled